Regeneron starts Phase 3 trial of Covid-19 antibody cocktail
The biotechnology company Regeneron announced the late-stage clinical trials of REGN-COV2, its investigational double antibody cocktail for the treatment and prevention of Covid-19, in a news release on Monday. Specifically the release noted that a Phase 3 trial of the drug will assess its ability to prevent coronavirus infection among uninfected people who have had … Read more